<DOC>
	<DOCNO>NCT00665847</DOCNO>
	<brief_summary>The purpose study determine safety antiviral activity etravirine treatment-experienced human immunodeficiency virus ( HIV ) infect child adolescent .</brief_summary>
	<brief_title>TMC125-TiDP35-C213 : Safety Antiviral Activity Etravirine ( TMC125 ) Treatment-Experienced , HIV Infected Children Adolescents</brief_title>
	<detailed_description>The study design single arm treatment ( patient assign receive etravirine ) , open label ( patient know identity treatment receive ) safety antiviral activity Etravirine ( TMC125 ) treatment-experienced , HIV infect child adolescent 6 17 year age . Etravirine new drug belonging NNRTI ( non-nucleoside reverse transcriptase inhibitor ) drug class slow growth human immunodeficiency virus ( HIV ) . This drug test safety effectiveness adult , however , data drug 's long-term safety antiviral activity child adolescent . This study last maximum 48 week . A total 100 ptients receive etravirine tablet base body weight investigator select optimized background regimen ( OBR ) least 2 antiretrovirals ( ARVs ) , consist boost protease inhibitor ( PI ) nucleoside reverse transcriptase inhibitor ( ) ( NRTI [ ] ) . Use enfuvirtide optional . Safety monitor throughout study .</detailed_description>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>HIV1 infect Body weight accord age within 1090th percentile CDC growth chart On steady antiretroviral therapy regimen least 8 week screen willing remain regimen baseline HIV viral load 1,000 copies/ml great study entry Parent legal guardian willing provide inform consent , necessary The Key Exclusion Criteria : Evidence resistance etravirinel Any grade 3 4 toxicity ( More information available protocol ) Use disallow concomitant therapy ( specify protocol ) Currently active AIDS defining illness ( category C ) Active hepatitis A , B C virus infection Any clinically significant disease finding , opinion investigator , would interfere study Receipt ARV nonARV investigational medication investigational vaccine within 30 day prior screen History clinically significant allergy hypersensitivity excipients investigational medication ( TMC125 )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>TMC125-TiDP35-C213</keyword>
	<keyword>TMC125-C213</keyword>
</DOC>